Osteoporosis risk in premenopausal women
- PMID: 19249949
- DOI: 10.1592/phco.29.3.305
Osteoporosis risk in premenopausal women
Abstract
Although clinically significant bone loss and fractures in healthy premenopausal women are rare, more women are seeking evaluation for osteoporosis from their health care providers. As pharmacists are in an ideal position to influence the management of premenopausal women with osteoporosis, it is important that pharmacists understand the available data on bone loss, fractures, and risk factors and secondary causes for osteoporosis, as well as when to recommend testing and treatment in premenopausal women. Limited data are available; therefore, we conducted a MEDLINE search of the literature from January 1993-August 2008. Studies evaluating bone loss, fractures, and fracture risk in healthy premenopausal women were targeted and summarized; most recommendations are based on expert opinion. A small but statistically significant loss in bone mineral density of 0.25-1%/year by dual-energy x-ray absorptiometry is seen healthy premenopausal women; the clinical significance of this is unknown. Whereas absolute fracture risk is low, premenopausal fractures appear to increase postmenopausal fracture risk by 1.5-3-fold. Risk factors for low bone density appear to be similar between pre- and postmenopausal women. Bone density screening in healthy premenopausal women is not recommended, but bone mineral density testing is advisable for those who have conditions or who receive drug therapy that may cause secondary bone loss. Lifestyle modification emphasizing bone-healthy habits such as adequate calcium and vitamin D nutrition, regular exercise, limitation of caffeine and alcohol consumption, and avoidance of tobacco are essential to the management of osteoporosis risk. The efficacy and safety of osteoporosis drugs have not been adequately demonstrated in premenopausal women. Therefore, pharmacologic interventions cannot be recommended in young women with low bone mass but may be considered in those having a more significant fracture risk, such as those with a previous low-trauma fracture or an identified secondary cause for bone loss.
Similar articles
-
Premenopausal osteoporosis.Minerva Med. 2008 Feb;99(1):55-63. Minerva Med. 2008. PMID: 18299696 Review.
-
Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.Menopause. 2010 Jan-Feb;17(1):25-54; quiz 55-6. doi: 10.1097/gme.0b013e3181c617e6. Menopause. 2010. PMID: 20061894
-
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.Cancer Treat Rev. 2008;34 Suppl 1:S3-18. doi: 10.1016/j.ctrv.2008.03.007. Epub 2008 Jun 2. Cancer Treat Rev. 2008. PMID: 18515009
-
Preventing osteoporotic fractures in older people.Practitioner. 2011 Jan;255(1736):19-22, 2-3. Practitioner. 2011. PMID: 21370710
-
Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?Cancer Treat Rev. 2012 Oct;38(6):798-806. doi: 10.1016/j.ctrv.2012.02.008. Epub 2012 Mar 18. Cancer Treat Rev. 2012. PMID: 22429722 Review.
Cited by
-
Predicting osteoporosis with body compositions in postmenopausal women: a non-invasive method.J Orthop Surg Res. 2021 Mar 24;16(1):215. doi: 10.1186/s13018-021-02351-3. J Orthop Surg Res. 2021. PMID: 33761975 Free PMC article.
-
Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women.Environ Health Perspect. 2020 Nov;128(11):117004. doi: 10.1289/EHP7017. Epub 2020 Nov 18. Environ Health Perspect. 2020. PMID: 33206002 Free PMC article.
-
Increased serum osteopontin is a risk factor for osteoporosis in menopausal women.Osteoporos Int. 2010 Aug;21(8):1401-9. doi: 10.1007/s00198-009-1107-7. Epub 2010 Mar 18. Osteoporos Int. 2010. PMID: 20238102
-
Skeletal manifestations of treatment of breast cancer on premenopausal women.Curr Osteoporos Rep. 2013 Dec;11(4):311-8. doi: 10.1007/s11914-013-0181-0. Curr Osteoporos Rep. 2013. PMID: 24126616 Review.
-
Steroidal contraceptive use is associated with lower bone mineral density in polycystic ovary syndrome.Endocrine. 2015 Dec;50(3):811-5. doi: 10.1007/s12020-015-0625-7. Epub 2015 May 10. Endocrine. 2015. PMID: 25957668
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials